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Mutations in the frataxin gene cause neurodegeneration and demyelination in Friedreich's ataxia. We showed earlier that frataxin deficiency
causes primary iron–sulfur cluster defects, and later causes defects in heme and cytochrome c hemoprotein levels. Iron–sulfur (Fe/S) clusters are
required in two enzymes of heme biosynthesis in humans i.e. in ferrochelatase and adrenodoxin. However, decreases in ferrochelatase activity
have not been observed in frataxin-deficient HeLa cells or patient lymphoblasts. We knocked down frataxin in oligodendroglioma cells using
siRNA, which produced significant defects in the activity of the Fe/S cluster enzymes adrenodoxin and aconitase, the adrenodoxin product heme
a, and cytochrome oxidase, for which heme a serves as a prosthetic group. Exogenous hemin produced a significant rescue of adrenodoxin,
aconitase, heme a levels and cytochrome oxidase activity. Thus hemin rescues iron–sulfur cluster defects that are the result of frataxin-deficiency,
perhaps as a consequence of increasing the pool of bioavailable iron, and thus should be more fully tested for beneficial effects in Friedreich's
ataxia models.
© 2007 Elsevier B.V. All rights reserved.Keywords: RNAi; Frataxin; Iron–sulfur cluster; Heme; Adrenodoxin; Hemin; Theraphy1. Introduction
Mutations in the frataxin gene result in deficiency of the
frataxin protein, expressed in mitochondria, causing the
neurodegenerative disease Friedreich's ataxia (FRDA).
Although the primary physiological role of frataxin has been
debated, a demonstrated function of frataxin is the support of
iron–sulfur (Fe/S) clusters [1–3], which function in iron–sulfur
enzymes inside mitochondria.
A microarray study carried out with lymphoblasts and
fibroblasts from FRDA patients, human neural cells, and cardiac
cells from knockout mice showed that the most consistent
transcriptional consequence of frataxin deficiency was an
inhibition of the heme pathway transcript, coproporphyrinogen
oxidase [4].⁎ Corresponding author. Tel.: +1 5307549665; fax: +1 5307549342.
E-mail address: gcortopassi@ucdavis.edu (G. Cortopassi).
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doi:10.1016/j.bbadis.2007.04.001Furthermore, we observed elevated protoporphyrin IX and
heme b levels, and deficiency of hemes a and c and cytochrome
oxidase in lymphoblasts from Friedreich's patients [4,5]. Work
with an inducible knockdown model showed that Fe/S
functions decline rapidly after frataxin deficiency, whereas
the heme defect occurs after the decline of Fe/S function in the
mitochondria. This is consistent with the idea that heme
deficiency is a consequence of a mitochondrial Fe/S cluster
defect [6].
There are two known Fe/S enzymes in mammalian heme
biosynthesis, ferrochelatase and adrenodoxin. Recently we
demonstrated that the activity of ferrochelatase in cells from
patients with FRDA is not decreased [5], consistent with work
from other groups [7].
The only other Fe/S enzyme besides ferrochelatase known to
participate in the heme biosynthetic pathway is adrenodoxin,
which carries out the first step of the conversion of heme O to
heme a, that is required for cytochrome oxidase activity. Thus
we knocked down frataxin levels using siRNA in a human
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adrenodoxin activity, decreased heme a levels, decreased
cytochrome oxidase activity, and decreased heme c level.
To see if exogenous heme could rescue these frataxin-
dependent effects, we supplemented the frataxin-deficient
HOGs with hemin, and observed a significant rescue of adreno-
doxin, aconitase, and increased cytochrome oxidase activity and
heme a levels, suggesting that hemin supplementation may be a
rational therapeutic strategy for FRDA patients.
2. Results
2.1. There are two iron–sulfur cluster enzymes in the heme
biosynthetic pathway
Frataxin is important for Fe/S cluster biogenesis in the
mitochondria [1–4,6,8,9]; its deficiency in human cells causes
a defect in heme a, a defect in the activity of the heme a-
containing enzyme cytochrome oxidase, and also in cyto-
chrome c and heme c levels [4,5]. There are only two
enzymes of the heme biosynthetic pathway known to have Fe/
S clusters, ferrochelatase and adrenodoxin (Fig. 1). Frataxin-
deficiency does not cause a decrease in the activity of the Fe/S
cluster enzyme ferrochelatase in FRDA lymphoblasts or HeLa
cells [1,4]. It has been proposed that the yeast homolog of the
human adrenodoxin (ferredoxin) is specifically involved in the
first step of conversion of heme O to heme a in the heme
biosynthetic pathway [10]. Heme a is in turn inserted in
cytochrome oxidase and acts as the electron transport
prosthetic group of the enzyme. Thus, we transfected human
HOG cells with frataxin siRNA to see if frataxin level has anFig. 1. Heme a and c biosynthetic pathwayeffect on the Fe/S enzyme adrenodoxin that participates in the
heme pathway.
The human oligodendroglioma cell line (HOG) was trans-
fected with frataxin-specific short interfering RNA (RNAi) [3],
which resulted in an overall strong inhibition of the targeted
message, and about 40% residual frataxin protein level (Fig. 2)
relative to transfection with the ‘scrambled’ RNAi, i.e. an RNAi
of identical nucleotide content but in randomized order.
2.2. Frataxin depletion reduces adrenodoxin and cytochrome
oxidase activity in oligodendroglioma cells
Adrenodoxin and cytochrome oxidase activities were
measured in scrambled and si-ftx HOGs; frataxin -deficiency
produced a similar and significant reduction, of about 35%, in
the activities of these two enzymes, compared with cells
transfected with the scrambled oligonucleotide (Fig. 3).
2.3. Frataxin-deficiency produces heme a and cytochrome c
heme deficiency
We previously observed that both hemes a [4] and
cytochrome c (i.e.‘heme c’), were deficient in cells from
Friedreich's patients, the latter perhaps as the result of some
feedback from the adrenodoxin deficiency [4,5].
Using HPLC we measured heme a levels in frataxin-
deficient HOG cells and observed that it was significantly
reduced with respect to the scrambled oligonucleotide (Fig.
4A). Cytochrome c heme amount was evaluated as previously
described [6] (Fig. 4C); and was significantly decreased in the
frataxin-depleted cells (Fig. 4B).s. Adapted from Schoenfeld et al. [4].
Fig. 2. Mitochondrial frataxin protein expression in oligodendroglial cells transfected with scrambledRNAi or frataxinRNAi (si-ftx). (left) oligodendroglioma cells
were transfected with frataxinRNAi or scrambled RNAi, mitochondria extracted and lysed and analyzed by Western blot. Reported are the results of the densitometry
measurements of the frataxin band normalized by an unspecific band appearing in the same blots. Error bars represent S.E.M. of 7 experiments. (Right) Example of
Western Blot detection of frataxin protein, using anti-frataxin antibody, 96 h post-transfection with scrambled RNAi or frataxin RNAi. A.U.=Arbitrary densitometry
Units. ***Pb0.0005 with paired t test.
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Because multiple hemes were decreased in frataxin-deficient
cells, we supplemented cells with exogenous heme as hemin
(10 μM). As higher levels of heme are toxic in some cell types
[11], the viability of all the cell lines used for our study was
evaluated after 22 h treatment. There was no decrease in
viability of the heme treated cells, as viabilities for treated and
untreated were ≥95% (data not shown).
The dose of hemin used for our experiments (10 μM)
stimulated the activities of both the Fe/S enzymes adrenodoxin
and aconitase (Fig. 5). To exclude that the increased Fe/S
enzyme activities were caused by the induction of frataxin
expression by hemin, which has been suggested by Sarsero and
coworkers in BHK cells [12], we measured the levels of frataxin
upon treatment with 10 μM hemin. Western blot and RT-PCR
analysis showed no difference in either the protein (Fig. 6) levels
or the relative mRNA levels by real-time QRTPCR (data not
shown) of frataxin after treatment for 22 h.
2.5. Hemin increases heme a levels and cytochrome oxidase
activity
Since hemin rescues the activity of adrenodoxin, which is
involved in heme a synthesis, we asked if it might rescue hemeFig. 3. Adrenodoxin (left) and cytochrome oxidase (right) activities in HOG cells
transfection and mitochondria isolated. For COX activity (here reported as % of scra
was obtained from the lysate as described in Materials and methods. The results a
Statistics: t test for paired values. **Pb0.005.a levels, and consequently cytochrome oxidase activity. Hemin
administration did increase heme a levels and cytochrome
oxidase activity in siRNA treated cells (Fig. 7).
3. Discussion
3.1. Frataxin-deficiency causes adrenodoxin and cytochrome
oxidase deficiency
Frataxin's major physiological role appears to be in iron–
sulfur (Fe/S) cluster biosynthesis [1–3,13]. In the last few years
studies conducted in yeast and mammalian cells have supported
an involvement of frataxin in heme synthesis [4,5,14,15]. There
are two known Fe/S cluster enzymes in the heme synthesis
pathway, ferrochelatase and adrenodoxin, and there have been
reports that frataxin binds ferrochelatase [16]. We first set out to
assay ferrochelatase from FRDA patient's cells, but observed,
like another study, no decrease in ferrochelatase activity [1,4].
We have gone on to show that frataxin-deficiency reliably
produces the induction of the heme pathway transcript ALAS1
in another mammalian model system, and that this always
follows a defect in mitochondrial Fe/S cluster status [5].
Therefore, we attempted to understand how frataxin, which
affects Fe/S clusters and produces a defect in mitochondrial
heme a and cytochrome oxidase activity, could affect hemetransfected with scrambled and si-ftx RNAi. Cells were collected 4 days after
mbled average) “fresh” permeabilized mitochondria were used; the Adx activity
re reported as mean±S.E.M. of 6 (Adx) and 9 (COX) different transfections.
Fig. 4. (A) Heme a and (B) cytochrome c heme levels in scrambled and si-ftx transfected HOGs. Heme c staining (C, example) was carried out as described in
Materials and methods. Results are average of 8 different experiments. Mean±S.E.M. is reported. A.U.=Arbitrary Units. *Pb0.05 calculated by paired t test.
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We chose to study this in oligodendroglioma cells, as we have
recently observed that mitochondrial defects specifically affect
oligodendrocyte-specific transcripts [17].
Heme a is the product of the activity of another matrix
mitochondrial Fe/S enzyme, adrenodoxin (Adx) (See Fig. 1). In
yeast, adrenodoxin (Yah1) and adrenodoxin reductase (Arh1)
are well characterized and are involved in heme a biosynthesis
[18,19] and in Fe/S cluster assembly [20]. Adrenodoxin and
adrenodoxin reductase provide electrons for the first step of
transformation of heme O into heme a.
We demonstrated significant heme a and c deficiency, and a
significant defect also in heme a-containing enzyme cyto-
chrome oxidase, confirming the previous results we obtained in
lymphoblasts from FRDA patients [4].
A heme-a deficiency, leading to cytochrome oxidase
deficiency, may be relevant to the pathogenetic mechanism of
FRDA, which causes degeneration of dorsal root ganglion
neurons, for several reasons. Firstly, it has been shown thatFig. 5. Adrenodoxin (left) and aconitase (right) activities in HOG scrambled and si
are the results of 3 (for adrenodoxin activity) and 6 (for aconitase activity) differen
two-tailed t test.inhibition of heme metabolism impairs cytochrome oxidase
activity, triggers mitochondrial damage, oxidative stress, and
iron accumulation, all of which are hallmarks of FRDA [21].
Secondly, previous studies have shown that cultures of
myelinated mouse dorsal root ganglia exhibit intense heme
fluorescence localized in myelin sheaths but not in axons. Also,
treatment with a heme-pathway inhibitor caused a specific
demyelination of the dorsal root ganglia [22].
Thirdly, inhibitors of cytochrome oxidase activity (carbon
monoxide, cyanide) and chelators of the copper cofactor
required for cytochrome oxidase activity (cuprizone), are
known to cause a selective demyelination [23–25].
Fourthly, cytochrome oxidase transcripts are normally up-
regulated in the process of oligodendrocyte differentiation
(Schoenfeld, in preparation).
Taken together, these data suggest that the frataxin-dependent
defect in heme a and cytochrome oxidase deficiency may be
relevant to the demyelinating phenotype observed in FRDA
[26,27].-ftx mitochondria untreated and treated with 10 μM hemin for 22 h. Reported
t transfections expressed as mean±S.E.M. Statistics were carried out by paired
Fig. 6. Mitochondrial frataxin protein expression in oligodendroglial cells
transfected with scrambledRNAi or frataxinRNAi (si-ftx), upon treatment of
10 μM hemin for 22 h. Oligodendroglioma cells were transfected with
frataxinRNAi or scrambled RNAi, mitochondria extracted and lysed and
analyzed by Western blot. Every mitochondrial extract was normalized for total
mitochondrial protein and the densitometry results reported as ratio between
units of frataxin and units of one unspecific band appearing in the same blots;
results are expressed as % of the average of the scrambled samples and error bars
represent S.E.M. of 7 experiments.
777E. Napoli et al. / Biochimica et Biophysica Acta 1772 (2007) 773–7803.2. Exogenous hemin rescues frataxin-dependent defects in
heme a, adrenodoxin, aconitase and cytochrome oxidase
Because frataxin-deficiency produced heme deficiency, we
tried to rescue these effects with exogenous heme. We observed
significant rescue for the activities of adrenodoxin and
aconitase, both Fe/S enzymes, for the activity of the heme a-
containing cytochrome oxidase, and for the heme a levels
themselves.
The rescue of the Fe/S enzymes adrenodoxin and aconitase
confirms what was previously shown in one publication for
aconitase [28], i.e. that exogenous hemin stimulates the activity
of Fe/S enzymes. Since Friedreich's ataxia seems to be a disease
of Fe/S biogenesis, this could be relevant for therapy.
Since we demonstrated that hemin produced no increase in
frataxin protein or mRNA relative expression, one possible
explanation for the stimulation of Fe/S enzyme activities byFig. 7. Heme a (left) and Cytochrome oxidase (COX) activity (right) in scrambled
duplicate. Statistics by one-tailed t test for paired values.heme is that heme and frataxin work together to serve as a source
of bioavailable iron in the biosynthesis of iron–sulfur clusters.
Therefore a deficiency of frataxin, which decreases availability
of iron for Fe/S synthesis, may be overcome by increasing the
bioavailability of iron, as heme-iron.
The administration of hemin restores the activity of enzymes
that have been shown to be defective in FRDA, suggesting that
heme-based strategies should be considered therapeutically. In
some ways these results seem consistent with recent reports that
erythropoietin, which is known to stimulate heme synthesis, can
rescue defects observed in frataxin-deficient cells [29]. How-
ever, given the iron overload observed in some hearts of FRDA
patients, also in the context of EPO administration, further
testing in cell and animal models to work out this mechanism
should be done.
3.3. Possible therapeutic use of hemin in FRDA
Up to now a number of therapeutic approaches have been
proposed for Friedreich's ataxia [30–34], and none appears to
alleviate the neurological signs. Idebenone appears to relieve
some of the cardiac hypertrophy in small studies [30–32]; but
questions about the use of idebenone as an antioxidant have
been raised when it was proven that it actually induces an
increased superoxide production in submitochondrial fractions
[35].
On the basis of our results demonstrating a heme imbalance
in frataxin deficient cells [4] and on recent findings which relate
frataxin function to heme synthesis/homeostasis, we propose
the consideration of hemin as possible therapeutic approach for
the treatment of Friedreich's ataxia. Hemin therapy has already
been demonstrated to be effective in the treatment of heme-
deficiency related disorders such as porphyria [36]. However,
given the possibility of iron toxicity problems, work should first
be carried out in cellular and animal models.
3.4. Summary and prospects
In summary, the data presented here demonstrate that
frataxin deficiency produces adrenodoxin, aconitase, andand Si-ftx HOGs. Results are the average±S.E.M of 6 different experiments in
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deficiency in a myelin-producing cell.
This provides the first direct connection between the iron–
sulfur cluster defects observed in FRDA, and the heme defects
observed by ours and other groups. The cytochrome oxidase
deficiency that is a result of heme deficiency could be relevant
to the demyelinating phenotype of FRDA. In addition, we
observe that exogenous heme administration increases activity
of the iron–sulfur cluster enzymes adrenodoxin and aconitase.
Thus heme-based stimulation of iron–sulfur cluster biogenesis
is a rational strategy for FRDA that should be further tested.
4. Materials and methods
4.1. Cell culture
Oligodendrocytes (HOG) were grown in DMEM containing 500 mg/L
glutamine and supplemented with 10% (v/v) FBS and maintained at 37° in a
humidified atmosphere containing 5% CO2.
4.2. RNA interference (RNAi) for inhibiting frataxin expression in
oligodendrogliomal cells
RNA interference technique was carried out as previously described [3].
HOG cells were incubated in regular DMEM for 24 h, washed twice in PBS and
then replaced with serum free OPTM 1 medium. A mixture of 200 nM si-RNA
(frataxin, si-ftx, AAC GUG GCC UCA ACC AGA UUU; or scrambled, CAG
UCG CGU UUG CGA CUG GdTdT) and Oligofectamine (Invitrogen,
Gaithersburg, MD, USA) was added to each T75 flask for 4 h, after which
OPTIM 1 medium containing 30% serum was added. The day after, the medium
was replaced with regular DMEM. Cells were harvested 72 h later and
mitochondriawere isolated.Western blot was used to confirm the frataxin protein
level.
4.3. Hemin treatment
For the studies of rescue with hemin one fraction of the cells was added of
10 μM hemin (Frontier Scientific, Inc., UT) and stored in incubator for 22 h; the
untreated fraction was added with the same amount of 100 mM of KOH, in
which hemin was dissolved.
4.4. Mitochondria isolation
Mitochondria were isolated from HOG cells transfected with scrambled and
si-ftx RNA, treated or untreated with 10 μM hemin. Approximately 1×108 cells
were enzymatically released using 2 ml of a 0.25% trypsin-EDTA solution/T75
flask for 3′ at 37 °C, following inactivation by addition of 8 ml culture medium
and harvested by centrifugation. The pellet was re-suspended with 4 ml of
isolation buffer (210 mM mannitol, 70 mM sucrose, 1 mM EGTA and 5 mM
HEPES, pH 7.2) for each gram of packed cells, treated with a final concentration
of 0.3 mg/ml digitonin for 2 min and centrifuged at 2800×g for 5′. The pellet
was then resuspended with 5 ml for each gram of initial packed cells and
homogenized with a chilled glass homogenator (20 passes). After several
centrifugation steps at 540×g the final spn was centrifuged and 10,000×g and the
final pellet was suspended with 0.1 ml of isolation buffer per gram of starting
cells, giving a protein concentration of approximately 15–20 mg/ml. For
determination of mitochondrial protein concentration, 2 μl of the mitochondrial
suspension were diluted 1:30 in double distilled water and the protein
concentration was estimated using the Bradford assay (Bio-Rad). The lysates
were prepared resuspending the mitochondrial pellet in about 100 μl per initial
gram of packed cell of the following lysis buffer: 50 mM Tris, pH 7.8, 100 mM
NaCl, 1 mM PMSF and 1% detergent (IGEPAL-CA630) for 30′ at 0 °C and
insoluble material removed by centrifugation at 16,000×g. The spn was
collected, the protein amount evaluated using the Bradford assay (Bio-Rad) and
the mitochondrial fraction stored at −80 °C.4.5. HPLC analysis of heme a
A Luna C-18, 4.6 _ 100 mm, 5 mm particle size column was used. Standards
were prepared from heme a (purified by Dr. Eric Hegg, University of Utah and
provided as a gift by Dr. Brian Gibney, Columbia University). All data were
analyzed using Millenium software (Waters, Milford, MA, USA).
Mitochondrial proteins (200 μg) were lysed with 5% HCl in acetone for
20 min on ice, centrifuged at 18,000×g for 5 min and supernatants collected for
analysis. The gradient used to measure heme a was from 100% buffer A (35%
acetonitrile, 0.08% trifluoroacetic acid) and 0% buffer B (0.08% trifluoroacetic
acid in acetonitrile) to 0% A and 100% B over 45 min with a flow rate of 1.0 ml/
min. Peaks were monitored at 405 nm.
4.6. Heme staining of cytochrome c
Untreated and treated mitochondrial extracts were separated on a 15% SDS/
PAGE gel. Heme staining was performed as previously described [37]. 40 μg of
mitochondrial protein from 3 different controls and 5 different FRDA
lymphoblast lines were loaded onto a 15% polyacrylamide gel and the
electrophoresis was performed at 130 mV for 60′. After the run the gel was fixed
in 10% TCA for 10′, washed 4 times for 5′ in double distilled water. The heme
staining is based on the oxidation of o-dianisidine, a probe which, in presence of
hydrogen peroxide (H2O2), can be oxidized by the peroxidase activity of some
heme-proteins (such as cytochrome c) changing color. The gel was soaked in a
solution of 50 mM trisodium citrate, 0.7% H2O2 and 1 mg/ml o-dianisidine for
40–60′ at 45 °C. 0.5 μg of horse heart purified cytochrome c was used as
positive controls. The band in correspondence of cytochrome c became evident
after 20′.
4.7. Western blot analysis of frataxin levels
Equal amounts of lysates (40 μg) untreated or treated with hemin were
resolved on a 15% SDS-polyacrylamide gel and then transferred to a
nitrocellulose membrane (Millipore, Bedford, MA) by electroblotting. After
blocking with 4% non-fat dry milk, the blot was incubated with anti-frataxin
(kind gift of Dr. Franco Taroni, Istituto Nazionale Neurologico Carlo Besta,
Milan, Italy) (1:2000) and developed with AP-conjugated secondary antibodies
using a chemiluminescent substrate.
4.8. Quantitative RT-PCR analysis
Total RNA was prepared using Qiagen Mini Kit (Qiagen, CA, USA), and
RNA concentration was determined by UV spectrophotometry. Reverse
transcription of 1 microgram RNA was performed using an RT-PCR kit
(Invitrogen, Gaithersburg, MD, USA), and reactions were performed in a
20 microliters volume. One microliter cDNA of RT reaction were used for PCR.
Quantitative PCR standard curves were set up for frataxin and GAPHD according
to a method previously described [38]. The PCR primers for GAPDH are: forward,
CCCCTGGCCAAGGTCATCCAT G; reverse, CAGTGAGCTTCCCGTT-
CAGTCC. The primers of PCR for frataxin are: forward, AAATCTG-
GAACTTTGGGCCAC; reverse, ACCTCAGCTGCATAATGAAGC. The PCR
reaction was previously described in detail [38]. Results were expressed as frataxin
m-RNA levels normalized by GAPDH.
4.9. COX, adrenodoxin and aconitase activity assays
Cytochrome oxidase (COX) activity was evaluated by the single
wavelength spectrophotometric assay previously described [39] with some
modifications. Intact mitochondria (2 μg) were permeabilized with 2.5 mM of
dodecylmaltoside in 0.17 M KH2PO4, pH 7.0 for 3′ at 30 °C, and, after
recording the baseline, the reaction was started with 100 mM of reduced
cytochrome c. COX activity was calculated from the pseudo-linear rate of
cytochrome c oxidation at 550 nm.
Adrenodoxin activity was evaluated in mitochondria lysates. To our
knowledge, there's no previous data about the direct measurement of Adx
activity in human biological samples so we followed the method described
for the purified protein [40] with some modification. Cytochrome c
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containing 0.1% Tween 20 at 23 °C. Reaction mixtures contained 0.05 μM
purified adrenodoxin reductase, 10 mM cytochrome c, and 350 μg of
mitochondrial protein. The reaction was initiated by the addition of 140 μM
NADPH. The absorption change at 550 nm was monitored, and the activity was
determined using Δε550=20 mM
−1 cm−1, after subtracting from the Δabs of
the samples prepared as described the Δabs of a “blank” w/o AdR.
The same mitochondrial lysates (150 μg protein) used for the evaluation of
Adx activity were utilized for the assay of aconitase activity by the
BIOXYTECH Aconitase-340 kit (OxisResearch, CA); NADPH formation was
recorded at 340 nm.
4.10. Statistics
Statistical analysis was carried out with Prism 3.03 software, the paired t
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